Remegen Co., Ltd.

This large, late-stage study is comparing a new three-drug combination to standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has high levels of a protein called HER2. The goal is to see if the new combination can better control the can…

This study is testing whether a new combination of three drugs can safely shrink tumors in people with HER2-positive breast cancer before they have surgery. The treatment aims to eliminate all cancer cells from the breast and lymph nodes by the time of surgery. Researchers will e…

This early-stage study is testing a new drug called RC278 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest and most effective dose and to see if the drug helps shrink tumors. The trial will enroll about 3…

This study is testing if a weekly injection called telitacicept can better control the symptoms of ocular myasthenia gravis, a condition that causes muscle weakness around the eyes. About 120 participants, aged 12 to 80, will receive either the drug or a placebo for 24 weeks whil…